Overall sales in the global market for kinase inhibitors were nearly $14 billion in 2008 which increased to $15.2 billion in 2009. By 2014, it is estimated to increase to $20.2 billion, at 5 year compound annual growth rate (CAGR) of 5.8%.
The largest segment receptor tyrosine kinase inhibitors market was nearly $9.4 billion in 2008; which increased to $10 billion in 2009. This is expected to rise to $13.1 billion in 2014, a CAGR of 5.5%.
Sales in serine/threonine kinase inhibitors (STKIs) reached approximately $512 million in 2008. This further increased to $855 million in 2009 and is projected to reach $1.4 billion in 2014, at a CAGR of 10.7%.
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study was to determine the current status of the kinase inhibitor industry and assess its growth potential over a 5-year period from 2009 to 2014. Only a handful such therapeutics have entered clinical use as of the end of 2009. For each, we have examined the drug development process, major challenges, and achievements and, where applicable, the projected market for each of these drugs through 2014.
We were particularly interested in up-and-coming kinase inhibitors in clinical trials and preclinical development. We identify the leading candidates in each kinase inhibitor class by molecular target and by disease application.
Our key objective is to present a comprehensive analysis of the current market and its future direction.
REASONS FOR DOING THIS STUDY
Human protein kinases are intriguing drug targets, in part, because they regulate a wide variety of signaling pathways and include more than 500 distinct protein molecules. Synthetic inhibitors of protein kinases include small molecules that may be easily administered as oral therapeutic compounds. These inhibitors can rapidly and often specifically alter the activation state of a target kinase.
We were interested in determining the potential for protein kinase inhibitors in the clinical treatment of major diseases, including cancer, heart disease, inflammatory disorders, diabetes, macular degeneration, and neurological disorders.
We have compiled a detailed description of kinase inhibitor compounds for clinical use. The study includes technological descriptions and challenges, applications, major players, international aspects, and projected growth through 2014.
This study will be of interest to members of the pharmaceutical, healthcare, and biotechnology industries. It will also be a valuable resource for investors in the biotechnology and pharmaceutical sectors. It is written in such a way as to be accessible to the businessperson while maintaining a high level of technical detail.
SCOPE OF REPORT
The scope of this study encompasses technologies employed in the pharmacogenomics industry. For each kinase inhibitor type in clinical use, BCC has analyzed the evidence of efficacy, technical limitations, and current market status and presents forecasts of growth over the next 5 years. We have emphasized the potential for additional novel applications and new competitive threats.
We examine the role of government regulations, patents, and factors affecting the industry worldwide. In addition, we analyze how the development of new kinase inhibitors is translating into new medical therapies for specific disease targets.
The market assessments provided have been assembled based on publicly available information from January 2006 up to and including 2009-10-15. The base year for this report is 2009 and forecast data are provided through 2014. In cases where data for 2009 were not available, figures were extrapolated from 2008 statistics, half-year figures for 2009, and historical trends between 2005 and 2008. Market figures are based on current dollars, and inflation is not computed into the projection figures. Interviews were also used to adjust market size estimates as well as to formulate market projections.
The field of kinase inhibitor development is still immature and the reader is cautioned to use the report data as a guide to assess trends, developments, and challenges that the industry faces.
The information contained in this report has been assembled from both primary and secondary data. Primary research was conducted via in-person, telephone, and e-mail interviews with selected industry professionals, research scientists, and laboratory heads to discover the most recent developments in their fields of interest. Secondary data was collected via a comprehensive search of the scientific, peer-reviewed literature, clinical trial reports and databases, industry trade media, company websites, annual reports, and industry press releases.
Brian Lawler has more than 4 years of experience working as an analyst covering the pharmaceutical and biotechnology industries. Trained at the University of Southern California, he holds a B.A. degree in economics.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
Examine BCC’s complete catalog of Market Research Reports and place direct orders
Subscribe to any of BCC’s many industry newsletters
Read announcements of recently published reports and newly launched newsletters
Register for BCC’s well-known conferences
Request additional information on any BCC product
Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Published - Jan-2006|
Analyst - Amy Brock|
Code - BIO053A
The worldwide market for kinase inhibitors for clinical use will reach $4.63 billion in 2005 and will rise at an average annual growth rate (AAGR) of 20.6% to $11.8 billion by 2010.
Receptor tyrosine kinase inhibitors comprise 49.8% of the total market in 2005 and are projected to grow at an AAGR of 26.6% to account for 63.7% of the total in 2010.
Nonreceptor tyrosine kinase inhibitors, consisting of BCR-Abl kinase inhibitor, reached sales of $1.86 billion in 2005. They are projected to increase at an AAGR of 13.7% to reach $3.56 billion in 2010.
The major disease application for kinase inhibitors is oncology that comprised nearly 90% of kinase inhibitor sales in 2005 and is expected to grow at an AAGR of 21.5%.
Need a custom data table, graph or complete report? Tell us more.
Join our mailing list for the latest report releases and upcoming event notifications.
Thank you for your interest in BCC Research. You will be added to our mailing list.
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth opportunities, market sizing, technologies, applications, supply chains and companies with the singular goal of helping you make informed business decisions, free of noise and hype.